Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05349474 · ClinicalTrials.gov registry record · Early Phase 1
Metformin Treatment in Progressive Multiple Sclerosis
A Early Phase 1 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 23
- Enrollment target
NCT05349474: Completed Early Phase 1 study, sponsored by University of California, Los Angeles.
NCT05349474 is a Early Phase 1 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 23 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (57% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05349474, a Early Phase 1 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety of metformin for treatment of progressive multiple sclerosis
Primary Outcome
number of patients with adverse events comparing the two treatment groups
Interventions
- DRUG Metformin 500 Mg Oral Tablet, up to 4 tablets a day
- DRUG Placebo oral tablet identical to metformin, up to 4 tablets a day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2022-04-26 |
| Est. Completion | 2025-05-30 |
| Phase | Early Phase 1 |
What the finished NCT05349474 record still lists
NCT05349474 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (57% lower).
The record links to 0 conditions, and to 2 interventions - of which Metformin 500 Mg Oral Tablet, up to 4 tablets a day is the first listed.
NCT05349474 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05349474 about?
NCT05349474 is a clinical study titled "Metformin Treatment in Progressive Multiple Sclerosis". The purpose of this study is to assess the safety of metformin for treatment of progressive multiple sclerosis
What is the current status of trial NCT05349474?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 23 participants. The study started on 2022-04-26. Estimated completion is 2025-05-30.
What interventions are being tested in trial NCT05349474?
The interventions under investigation include: Metformin 500 Mg Oral Tablet, up to 4 tablets a day (DRUG), Placebo oral tablet identical to metformin, up to 4 tablets a day (DRUG).
Who is sponsoring clinical trial NCT05349474?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05349474's enrollment target sits among peer trials
23 1088th of 2000 higher than 897 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI